Skip to content
OAMMEDICAL VENTURES All perspectives
Longevity & data

Longevity is a measurement problem first

You cannot extend what you cannot see. The companies we back turn diagnostics into decisions.

By OAM Longevity Unit·9 April 2026·6 min read

Longevity is sold as a supplement or a protocol. In practice, healthy ageing starts somewhere far less glamorous: measurement — and the software that makes measurement actionable.

From data to decisions

The body gives early signals long before disease appears — in metabolism, inflammation, cardiovascular markers, sleep and body composition. The opportunity we fund is the layer that reads those signals over time and turns them into protocols that actually change the trajectory.

Prevention is not a slogan. It is the difference between acting on a number and reacting to a diagnosis.

Where the value sits

Hardware and labs are commoditising. The durable value is in the data platform: longitudinal, multi-signal, and trusted enough to drive clinical decisions. That is where we want to invest.

None of this promises more years. It improves the odds the years you have are active and well — a goal worth measuring precisely, and worth building a company around.

OAM
OAM Longevity Unit
OAM Medical Ventures
Continue reading
LanguageENعربي